Indivior Pharmaceuticals Inc
INDV | NASDAQ
$35.41
+$0.53 (+1.52%)
Sep 21, 2026, 1:19 PM ET · Market open
Company Profile
Indivior Pharmaceuticals Inc. operates as a holding company, primarily engaged in the research, production, and distribution of buprenorphine-based prescription medications designed to treat opioid dependence. Its product lineup features key pharmaceuticals such as Suboxone Film, Suboxone Tablet, and Subutex Tablet. The company organizes its business into several geographical regions: the United States, the United Kingdom, and the broader international market. Established on September 26, 2014, its corporate headquarters are located in North Chesterfield, Virginia.
Key Executives
| Name | Position |
|---|---|
| Joseph J. Ciaffoni | Chief Executive Officer & Director |
| Jeffrey W. Burris | Chief Legal Officer |
| Ryan Preblick | Chief Financial Officer |
| Alice G. Givens | Company Secretary |
| Angela Colon-Mahoney | Chief Human Resources Officer |
| Ann Wheeler | Chief Medical Officer |
| Christian Heidbreder | Chief Scientific Officer |
| Jason Thompson | Vice President of Investor Relations |
| Kevin L. Espinoza | Chief Integrity & Compliance Officer |
| Patrick A. Barry | Chief Commercial Officer |
| Vanessa Procter | Executive Vice President of Corporate Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 28, 2026 | S-4 | Filing |
| Aug 27, 2026 | 4 | Filing |
| Aug 13, 2026 | SC 13D/A | [Amend] Filing |
| Aug 05, 2026 | 4 | Filing |
| Aug 04, 2026 | 425 | Filing |
| Aug 03, 2026 | 425 | Filing |
| Aug 03, 2026 | 10-Q | Quarterly Report |
| Aug 03, 2026 | 425 | Filing |
| Aug 03, 2026 | 8-K | Current Report |
| Aug 03, 2026 | 425 | Filing |
Indivior Pharmaceuticals Inc
| Country | United States |
| IPO Date | Dec 28, 2014 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 833 |
| CEO | Joseph J. Ciaffoni |
Contact Details
10710 Midlothian Turnpike North Chesterfield,
Virginia 23235 United States
Stock Details
| Ticker Symbol | INDV |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001625297 |
| CUSIP Number | 45579U109 |
| ISIN Number | US45579U1097 |
| SIC Code | 2834 |
Recent News
- 2 months ago / zacks.comINDV to Merge With Supernus, Beats on Q2 Earnings, Raises '26 Outlook
- 2 months ago / prnewswire.com$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Indivior Pharmaceuticals, Inc. (NASDAQ: INDV)
- 3 months ago / zacks.comINDV Stock: What Sublocade Growth Signals for 2026
- 4 months ago / zacks.com5 Top-Ranked Efficient Stocks Beating Industry Peers on Key Metrics
- 4 months ago / globenewswire.comNew Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization
- 5 months ago / globenewswire.comSurvey of Correctional Facility Staff: Monthly Opioid Treatment Shot May Help Reduce Medication Misuse
- 6 months ago / globenewswire.comNew Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional Facilities
- 6 months ago / globenewswire.comNew Study Shows Adherence to Monthly Injectable Buprenorphine Linked to Lower Healthcare Utilization and Costs in Opioid Use Disorder
Add to Watchlist
Select watchlists to add or remove INDV